The ARB-type hypertension singular drug market has suffered from depression… Boryung is the only one grown
While the single drug market for domestic ARB-type hypertension treatments has been decreased, Boryung Pharm has kept its steady growth.
According to the Hana Daetoo Securities’s analysis result of the UBIST data, the Boryung Pharm’s ‘Kanarb’ recorded KRW 7.3 billion outpatient prescription expe...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
